&w=3840&q=100)
Gland Pharma share rises 2% in trade on Wednesday, June 4; here's why
Gland Pharma share price: Pharmaceutical company Gland Pharma shares increased as much as 1.58 per cent to hit an intraday high of 1,619 per share on Wednesday, June 4, 2025.
At 11:10 AM, Gland Pharma shares continued to trade near day's high, up 1.33 per cent at 1615 per share.
Why did Gland Pharma share price rise?
Gland Pharma shares rose after it secured United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL.
'Gland Pharma Limited (Gland or Company), a generic injectable & ophthalmicfocused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL,' Gland Pharma said, in a press release.
Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Giapreza of La Jolla Pharma LLC, the company revealed.
'Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity,' the company claimed.
The product had US sales of approximately $58 million for the twelve months ending March 2025, according to IQVIA.
Gland Pharma Q4 results
Gland Pharma reported a 3 per cent year-on-year (YoY) decline in its consolidated net profit to ₹186.5 crore for the fourth quarter ended March 2025 (Q4FY25), compared to ₹192.4 crore in the same period last year.
Revenue from operations fell 7 per cent YoY to ₹1,424.9 crore from ₹1,537.5 crore. The company's Ebitda stood at ₹347.5 crore, marginally down from ₹358.7 crore a year ago.
However, the Ebitda margin improved to 24 per cent in Q4FY25, compared to 23 per cent in the corresponding quarter last year.
Research and development (R&D) expenses during the quarter were ₹50.3 crore, accounting for 4.9 per cent of revenue. For the full financial year FY25, R&D expenses stood at ₹192.2 crore, or 4.7 per cent of annual revenue.
Gland Pharma dividend
About Gland Pharma
Founded in 1978 in Hyderabad, Gland Pharma has evolved from a contract manufacturer of small-volume liquid parenterals to one of the largest injectable-focused pharmaceutical companies globally.
Operating predominantly under a B2B model, it has a presence in over 60 countries, including the US, Europe, Canada, Australia, and India.
The company's portfolio spans a wide range of sterile injectables such as vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, as well as oncology and ophthalmic products. Notably, it pioneered Heparin technology in India.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
19 hours ago
- Mint
Missed the pharma rebound? Gland Pharma, Cipla among 8 stocks that jumped up to 28% since April
Pharma stocks have made a big comeback in recent months, with companies such as Granules India, Gland Pharma, Dr. Reddy's Laboratories, Natco Pharma, Aurobindo Pharma, and Cipla rebounding sharply from their April lows, emerging as some of the top turnaround champions in the 2025 market recovery. Granules India led the pack with a 28% recovery from its April low of ₹ 422 apiece, now trading at ₹ 533. Gland Pharma followed with a 27.8% rise to ₹ 1,633 apiece. Likewise, shares of Dr. Reddy's Laboratories have gained 26%, while JB Chemicals & Pharmaceuticals, Zydus Lifesciences, Natco Pharma, Aurobindo Pharma, and Cipla have recovered in the range of 11.5% to 23%. The strong recovery in the select counters has boosted the Nifty Pharma index to regain 13% from April lows. The recent rebound in pharma stocks has been driven by a combination of sector-specific tailwinds, improving global trade sentiment, and renewed investor appetite for risk. Additionally, attractive valuations at lower levels have also encouraged value buying, leading to a notable turnaround in several key counters. Notably, investor sentiment toward pharma stocks received a boost after the US government excluded generic drugs from the Most Favored Nation (MFN) Pricing Policy. In mid-May, US President Trump signed Executive Order 14297 to implement the MFN policy, which aimed to lower US prescription drug prices by benchmarking them against the lowest prices in other developed countries. However, the US Department of Health and Human Services later clarified that generics would be exempt from these price cuts, a significant relief for Indian biosimilar and generic drug manufacturers, for whom the US remains a key export market. India exports 54% of its pharmaceutical production, and nearly one-third of this goes to the United States. Of the exports to the US, about 85% comprise formulations, primarily generics, while sales from biosimilars and innovator drugs remain low, according to credit rating agency Crisil. Generic drugs account for 90% of prescription sales volume in the US but represent only 13% of total prescription spending. The agency also noted that generic drug prices in the US are among the lowest globally, even compared to economically comparable countries. Meanwhile, India has proposed a range of measures as part of the ongoing trade negotiations with the US, placing the pharmaceutical sector at the center of the discussions. Mint earlier reported, citing two people familiar with the matter, that India's proposals include the supply of low-cost complex generic medicines at sharply reduced prices, patent reforms to allow earlier entry of generics into the US, increased US-based manufacturing by Indian pharma firms of active pharmaceutical ingredients (APIs) and fixed dosage forms (FDFs), and tariff exemptions for life-saving and critical medicines imported into India from the US. The pharmaceutical sector delivered a turnaround performance in the quarter ending March, driven by strong growth in the India business. Companies covered by the domestic brokerage firm Axis Securities reported a growth of 11.5% YoY and 1.6% QoQ in the Q4FY25. Gross margins improved to 66.1%, reflecting a 95 bps increase YoY and a 40 bps rise QoQ. This improvement was supported by the launch of niche products, low single-digit price erosion, a higher contribution from the Indian business in the product mix, and stable raw material prices. On a QoQ basis, the US business stood at $2,240 million, showing 7.7% YoY growth in constant currency (CC) terms, driven by volume growth in the base portfolio and moderate performance from the top drug (gRevlimid). In the domestic market, the Indian Pharmaceutical Market (IPM) recorded 8% YoY growth in Q4FY25. Overall, the brokerage anticipates a strong pipeline in segments such as biosimilars, GLP-1, and peptides over the next three years. Companies with a higher share of chronic portfolios are outperforming the IPM. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
Hans India
a day ago
- Hans India
Wockhardt eyes $7 bn mkt opp for antibiotic Zaynich
New Delhi: Drugmaker Wockhardt said its novel antibiotic Zaynich has an addressable market opportunity of $7 billion in the US and Europe. The company said it has completed a pre-NDA (non-disclosure agreement) meeting with the US Food and Drug Administration (USFDA) in May 2025. Filing to the USFDA is slated in the second quarter of the current fiscal with potential launch in FY2026-27, Wockhardt Ltd said in a regulatory filing. The company plans for regulatory approval for the product in Europe and emerging markets in the second half of the current financial year, it added. Wockhardt said it has also filed for approval of Zaynich with the Drug Controller General of India (DCGI) and expects to launch the product in the domestic market in the second half of the current fiscal. The antibiotic, to be used against gram-negative infections, is expected to help 11 lakh cases in India alone, the Mumbai-based drug maker said.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.
